Professor Katie Watson joins Ethics Talk to consider key questions about clinical and legal risk management for clinicians trying keep patients safe and for patients with complex pregnancies trying to stay alive.
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Differentiating between best palliative care options and the curative and palliative potential of surgery is key to developing dual intentional clarity.
AMA J Ethics. 2021;23(10):E766-771. doi:
10.1001/amajethics.2021.766.
This narrative information graphic contextualizes the lack of current maternal morbidity and mortality data in the United States since the Dobbs v Jackson Women’s Health Organization decision in 2022.
AMA J Ethics. 2024;26(1):E92-93. doi:
10.1001/amajethics.2024.92.
The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions.
Despite the natural desire in obstetrics for a happy outcome, sometimes the common aggressive interventions will not help maintain a pregnancy until viability.